• Aprogen issued a correction to its Sept. 3 third-party share sale at its unit Aprogen Biologics.
• Proceeds reclassified to “other funds” of KRW 20 billion from an earlier plan for securities acquisition.
• Use of funds set as a loan to Einspec to support balance-sheet restructuring.
• Terms unchanged: 12,706,481 new shares at KRW 1,574 each to Aprogen, with a one-year lockup from listing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprogen Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260923800439), on September 23, 2026, and is solely responsible for the information contained therein.